


WHAT IS CLAIMED IS:

1. A compound represented by Formula A:



A

or a pharmaceutically acceptable salt thereof, wherein:

- 10 R¹, R², R³ and R⁴ are each independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl and C₁-5alkoxy,

wherein said C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl and C₁-5alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of:
 15 -F, -Cl, -Br, -I, -OH, C₁-8alkoxy and -CO₂H,

and any two of R¹, R², R³ and R⁴ may be joined together with the atoms to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms optionally containing 1 or 2 oxygen atoms;

20 R⁵ is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy,

wherein said C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of:
 25 -F, -Cl, -Br, -I, -OH and C₁-8alkoxy;

R⁶ is selected from the group consisting of: phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl and thienyl, each optionally substituted with one to three substituents independently
 30 selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, -NR⁷R⁸, -NO₂, phenyl, thienyl,

C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₂-4acyloxy,

5 wherein said phenyl, C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₁-4acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-8alkoxy, and

10 R⁶ may be substituted on two adjacent atoms to form a fused partially aromatic bicyclic ring of 9 to 12 atoms optionally containing one or two oxygen or sulfur groups, or both, and optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, and C₁-4alkyl;

15 R⁷ and R⁸ are independently selected from the group consisting of: -H, C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl, wherein said C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy, and

20 R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy;

25 U, V and W are independently selected from the group consisting of: -C(R⁹)- and -N-;




each R⁹ is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy,

30 wherein said C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-8alkoxy;


For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 4 to 8 membered ring, optionally containing 1 or 2 oxygen, sulfur or N(R¹⁰)

atoms, thus forming a fused partially aromatic bicyclic ring system of 8 to 12 atoms with the 6-membered aromatic ring to which R⁹ is attached;

- 5 X, Y and Z are independently selected from -C(R¹¹)=, -O-, -N=, -N(R¹²)- and -S- such that the resulting ring together with Q and T form an aromatic heterocycle;

Q and T are independently selected from  or , with the proviso that both Q and T are not  ;


- 10 R¹⁰, R¹¹ and R¹² are each independently selected from the group consisting of : -H, C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl, wherein said C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy;
- 15 J is selected from the group consisting of: -CO₂H, -PO₃H₂, -PO₂H₂, -SO₃H, -CONHSO₂R¹³, -PO(R¹³)OH,



5 R_{13} is selected from the group consisting of: C₁-C₄ alkyl, phenyl, $-CH_2OH$ and $CH(OH)$ -phenyl; and

each R_{14} is independently selected from the group consisting of: $-H$ and $-CH_3$.

10 2. A compound in accordance with Claim 1 represented by Formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

5

R¹, R², R³ and R⁴ are each independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl and C₁-5alkoxy,

10

wherein said C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl and C₁-5alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH, C₁-8alkoxy and -CO₂H,

15

and any two of R¹, R², R³ and R⁴ may be joined together with the atoms to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms optionally containing 1 or 2 oxygen atoms;

20

R⁵ is selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy,

25

R⁶ is selected from the group consisting of: phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizynyl and thienyl, each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, -NR⁷R⁸, -NO₂, phenyl, C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₂-4acyloxy,

30




wherein said phenyl, C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy,

C₃₋₆cycloalkoxy, C₁₋₄alkylthio and C₁₋₄acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₈alkoxy, and

- 5 R⁶ may be substituted on two adjacent atoms to form a fused partially aromatic bicyclic ring of 9 to 12 atoms optionally containing one or two oxygen or sulfur groups, or both, and optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, and C₁₋₄alkyl;
- 10 R⁷ and R⁸ are independently selected from the group consisting of: -H, C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy, and
- 15 R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy;
- 20 U, V and W are independently selected from the group consisting of: -C(R⁹)- and -N-;
- each R⁹ is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and C₁₋₄alkoxy,
- 25 wherein said C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and C₁₋₄alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₈alkoxy;

For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are
30 attached to form a 4 to 8 membered ring, optionally containing 1 or 2 oxygen, sulfur or N(R¹⁰) atoms, thus forming a fused partially aromatic bicyclic ring system of 8 to 12 atoms with the 6-membered aromatic ring to which R⁹ is attached;

X, Y and Z are independently selected from -C(R¹¹)=, -O-, -N=, -N(R¹²)- and -S- such that the
35 resulting ring together with Q and T form an aromatic heterocycle;

Q and T are independently selected from  or , with the proviso that both Q and T are not ; and

5 R¹⁰, R¹¹ and R¹² are each independently selected from the group consisting of: -H, C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl, wherein said C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy.

10 3. A compound according to Claim 2 wherein R⁵ is methyl.


4. A compound according to Claim 2 wherein R⁶ is selected from the group consisting of: phenyl and pyridinyl, each optionally substituted with one to three substituents independently selected from the group consisting of: F, -Cl, -Br, -I, -CN, -OH, -NR⁷R⁸, -NO₂,
15 C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy, C₁-4alkylthio, C₃-6cycloalkoxy and C₁-4acyloxy,

wherein said C₁-4alkyl, C₃-6cycloalkyl, C₂-4alkenyl, C₂-4alkynyl, C₁-4alkoxy, C₁-4alkylthio, C₃-6cycloalkoxy and C₁-4acyloxy are each optionally substituted from one up to the maximum
20 number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-8alkoxy; and

R⁷ and R⁸ are independently selected from the group consisting of: -H, C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl, wherein said C₁-6alkyl, C₂-6alkenyl and C₂-6alkynyl are each
25 optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy, and

R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring
30 is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy.

5. A compound according to Claim 2 wherein V and W are -CH-.
6. A compound according to Claim 2 of Formula Ia



or a pharmaceutically acceptable salt thereof, wherein:

- 10 R¹ and R² are independently selected from the group consisting of: -H, -OH and methyl or R¹ and R² may be joined together with the atoms to which they are attached to form cyclopropyl;

U and V are each independently selected from the group consisting of: -C(R⁹)- and -N-;

- 15 each R⁹ is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy, wherein said C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-8alkoxy, and

- 20 For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R⁹ is attached;

- 25 A is selected from the group consisting of: -N- and -C(R¹³)-, wherein R¹³ is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂;

- R^a is selected from the group consisting of: NR⁷R⁸, C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₁-4acyloxy, wherein said C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₁-4acyloxy are each optionally substituted from
 30 one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I and -OH;

R⁷ and R⁸ are independently selected from the group consisting of: -H and C₁-6alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy, and

5


R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy; and

10

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂.

15

7. A compound according to Claim 2 of Formula Ib



Ib

20 or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of: -H, -OH and methyl;

25 A is selected from the group consisting of: -N- and -C(R¹³)-, wherein R¹³ is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂;

R^a is selected from the group consisting of: NR⁷R⁸, C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₁-4acyloxy, wherein said C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, C₃-6cycloalkoxy, C₁-4alkylthio and C₁-4acyloxy are each optionally substituted from

one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I and -OH;

R⁷ and R⁸ are independently selected from the group consisting of: -H and C₁-6alkyl,


5 optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy, and

10 R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-5alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂.

15

8. A compound according to Claim 2 of Formula Ic



20

or a pharmaceutically acceptable salt thereof, wherein:

R¹ and R² are independently selected from the group consisting of: -H, -OH and methyl or R¹ and R² may be joined together with the atoms to which they are attached to form cyclopropyl;

25

U and V are each independently selected from the group consisting of: -C(R⁹)- and -N-;

each R⁹ is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy, wherein said C₁-4alkyl, C₂-4alkenyl, C₂-4alkynyl and C₁-4alkoxy are each optionally substituted with one to three substituents
 30 independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁-8alkoxy, and

For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R⁹ is attached;

5

A is selected from the group consisting of: -N- and -C(R¹³)-, wherein R¹³ is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂;

10

R^a is selected from the group consisting of: NR⁷R⁸, C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, C₃₋₆cycloalkoxy, C₁₋₄alkylthio and C₁₋₄acyloxy, wherein said C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, C₃₋₆cycloalkoxy, C₁₋₄alkylthio and C₁₋₄acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I and -OH;

15

R⁷ and R⁸ are independently selected from the group consisting of: -H and C₁₋₆alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy, and


20

R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy; and

25

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂.

9. A compound according to Claim 2 of Formula Id



30

or a pharmaceutically acceptable salt thereof, wherein:

R¹ and R² are independently selected from the group consisting of: -H, -OH and methyl or R¹ and R² may be joined together with the atoms to which they are attached to form cyclopropyl;

5

U and V are each independently selected from the group consisting of: -C(R⁹)- and -N-;

10

each R⁹ is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and C₁₋₄alkoxy, wherein said C₁₋₄alkyl, C₁₋₄alkenyl, C₁₋₄alkynyl and C₁₋₄alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₈alkoxy, and

15

R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R⁹ is attached;

A is selected from the group consisting of: -N- and -C(R¹³)-, wherein R¹³ is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂;

20

R^a is selected from the group consisting of: NR⁷R⁸, C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, C₃₋₆cycloalkoxy, C₁₋₄alkylthio and C₁₋₄acyloxy, wherein said C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, C₃₋₆cycloalkoxy, C₁₋₄alkylthio and C₁₋₄acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: -F, -Cl, -Br, -I and -OH;

25

R⁷ and R⁸ are independently selected from the group consisting of: -H and C₁₋₆alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy, and


30

R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -OH and C₁₋₅alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH₃, -OCH₃, -CF₃, ethynyl, -NO₂ and -NH₂.

10. A compound according to Claim 2 selected from the following table:

5



1e

Ex.	R ^a	R ^b	A	U	R ²	R ¹
1	<i>i</i> -PrO-	-CN	-CH=	=CH-	H	H
2	<i>i</i> -PrO-	Cl-	-CH=	=CH-	H	H
3	<i>i</i> -PrO-	Br-	-CH=	=CH-	H	H
4	<i>i</i> -PrO-	MeO-	-CH=	=CH-	H	H
5	<i>i</i> -PrO-	Me-	-CH=	=CH-	H	H
6	<i>i</i> -PrO-	F-	-CH=	=CH-	H	H
8	<i>i</i> -PrO-	-CF ₃	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
9	<i>i</i> -PrO-	-CF ₃	-CH=	=CH-	H	Me
10	<i>i</i> -PrO-	-CN	-CH=	=CH-	H	Me
11	<i>i</i> -PrO-	-CH ₃	-CH=	=CH-	H	Me
12	<i>i</i> -PrO-	-CF ₃	-CH=	=CH-	Me	H
13	<i>i</i> -PrO-	-CN	-CH=	=CH-	Me	H
14	<i>i</i> -PrO-	-CH ₃	-CH=	=CH-	Me	H
15	<i>i</i> -PrO-	Cl-	-N=	=CH-	H	H
16	<i>i</i> -Pr-NH-	Cl-	-N=	=CH-	H	H
17	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	H	H
18	pyrrolidinyl	Cl-	-N=	=CH-	H	H
19	morpholin-4-yl	Cl-	-N=	=CH-	H	H
20	<i>i</i> -Pr-N(Me)-	Cl-	-N=	=CH-	H	H

21	2,2,2-trifluoroethoxy	Cl-	-N=	=CH-	Me	H
22	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	Me	H
23	3,3-difluoropiperidinyl	Cl-	-N=	=CH-	Me	H
24	3,3,-difluoropyrrolidinyl	Cl-	-N=	=CH-	Me	H
25	morpholin-4-yl	-CF ₃	-N=	=CH-	Me	H
26	3,3,-difluoropyrrolidinyl	Cl-	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
27	2,2,2-trifluoroethoxy	Cl-	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
28	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
29	1-Me- <i>n</i> -PrO-	Cl-	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
30	<i>i</i> -PrO-	Cl-	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
31	<i>i</i> -Bu-	Cl-	-N=	=CH-	H	H
32	<i>i</i> -Pr-N(Me)-	I-	-N=	=CH-	H	H
33	<i>i</i> -Pr-N(Me)-	-CN	-N=	=CH-	H	H
34	3,3,-difluoropyrrolidinyl	I	-N=	=CH-	H	H
35	3,3,-difluoropyrrolidinyl	-CN	-N=	=CH-	H	H
36	<i>i</i> -PrO-	-CN	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
37	2,2,2-trifluoro-1-methylethoxy	-CN	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
38	<i>i</i> -PrO-	MeO-	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
39	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
40	2,2,2-trifluoro-	-CN	-CH=	=CH-	R ² and R ³ joined to	


	1-trifluoromethyl ethoxy				form cyclopropyl	
43	1-Me- <i>n</i> -PrO-	-CN	-CH=	=CH-	R ² and R ³ joined to form cyclopropyl	
44	2,2,2-trifluoro-1- methylethoxy	-CN	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
45	<i>i</i> -PrO-	I	-N=	=CH-	R ² and R ³ joined to form cyclopropyl	
48	Ethoxy	-CN	-N=	=CH-	H	H
49	2,2,2-trifluoro-1- methylethoxy	-CN	-N=	=CH-	H	H
50	2-Me- <i>n</i> -Pr-	-CN	-N=	=CH-	H	H
51	2-methyl-1,1- difluoro- <i>n</i> -propyl	H	-CH=	=CH-	H	H
52	2,2,2-trifluoro-1- methylethoxy	I-	-N=	=CH-	H	H
53	Cyclopentyloxy	Cl-	-CH=	=CH-	H	H
54	2-Me- <i>n</i> -PrO-	Cl-	-CH=	=CH-	H	H
55	2,2,2-trifluoro-1- methylethoxy	-CN	-CH=	=CH-	H	H
56	2,2,2-trifluoro-1- methylethoxy	Cl-	-CH=	=CH-	H	H
57	<i>i</i> -PrO-	Cl-	-C(Cl)=	=CH-	H	H
58	cyclopropylmethoxy	Cl-	-CH=	=CH-	H	H
60	2,2,2-trifluoro-1- methylethoxy	-NO ₂	-CH=	=CH-	H	H
61	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	H	H
62	2,2,2-trifluoro- 1-trifluoromethyl ethoxy	-CN	-CH=	=CH-	H	H
63	1-Me- <i>n</i> -PrO-	-CN	-CH=	=CH-	H	H
65	2,2,2-trifluoro-1- methylethoxy	-NH ₂	-CH=	=CH-	H	H
66	1-Me- <i>n</i> -PrO-	-CN	-CH=	=CH-	Me	H


67	2,2,2-trifluoro-1-trifluoromethyl ethoxy	-CN	-CH=	=CH-	Me	H
68	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	Me	H
69	<i>i</i> -PrO-	-CN	-CH=	=N-	H	H
70	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=N-	H	H
71	2,2,2-trifluoroethoxy	-CN	-CH=	=N-	H	H
72	2,2,2-trifluoro-1-trifluoromethyl ethoxy	-CN	-CH=	=N-	H	H
73	2,2,2-trifluoroethoxy	-CN	-CH=	=N-	Me	H
74	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=N-	Me	H
75	<i>i</i> -PrO-	-CF ₃	-CH=	=CH-	H	H
79	<i>i</i> -PrO-	-CN	-CH=	=CH-	OH	OH
80	<i>i</i> -PrO-	-CN	-CH=	=CH-	OH	OH








or a pharmaceutically acceptable salt of any of the compounds above.


11. A compound according to Claim 2 selected from the following table:







5

























or a pharmaceutically acceptable salt of any of the compounds above.

12. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

13. The method according to Claim 12 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

14. The method according to Claim 12 wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.

5 15. The method according to Claim 12 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis,
 10 glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata,
 15 keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma
 20 and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic
 25 nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis,
 30 leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or
 35 promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's

syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxins caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

16. The method according to Claim 12 wherein the immunoregulatory abnormality is selected from the group consisting of:

- 1) multiple sclerosis,
- 2) rheumatoid arthritis,
- 3) systemic lupus erythematosus,
- 4) psoriasis,
- 5) rejection of transplanted organ or tissue,
- 6) inflammatory bowel disease,
- 7) a malignancy of lymphoid origin,
- 8) acute and chronic lymphocytic leukemias and lymphomas and
- 9) insulin and non-insulin dependent diabetes.

17. A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

18. A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.

19. A method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said respiratory disease or condition.

5

20. The method according to Claim 19 wherein the respiratory disease or condition is selected from the group consisting of: asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, infant respiratory distress syndrome, cough, eosinophilic granuloma, respiratory syncytial virus bronchiolitis, bronchiectasis, idiopathic pulmonary fibrosis, acute lung injury and bronchiolitis obliterans organizing pneumonia.

10

21. A method for treating a disease or condition related to vascular integrity in a patient in need thereof, wherein the disease or condition is selected from the group consisting of: angioedemas, vasculitis, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, arteriosclerosis, atherosclerosis, aortitis syndrome, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, sepsis, pancreatitis, disease caused by histamine or leukotriene-C4 release, necrosis caused by toxin, viral hepatitis, shock or anoxia, senile dementia, and trauma, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to treat the disease or condition.

25


22. A method for treating a disease or condition associated with cerebral or pulmonary edema in a patient in need thereof, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to treat the disease or condition.

30

23. A method according to Claim 22 wherein the disease or condition is selected from the group consisting of: shock, sepsis, acute respiratory distress syndrome and brain edema.

35

24. A compound according to Claim 1 of Formula If:



If

or a pharmaceutically acceptable salt thereof, wherein:

5

R^1 and R^2 are -H, or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and V are $-C(R^9)-$;

10

each R^9 is -H, or

For U or V, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R^9 is attached;


15


R^a is selected from the group consisting of: C_{1-4} alkoxy and C_{3-6} cycloalkoxy, said C_{1-4} alkoxy and C_{3-6} cycloalkoxy groups optionally substituted from one up to the maximum number of substitutable positions with fluoro; and

20

R^b is selected from the group consisting of: C_{1-4} alkyl and C_{2-4} alkenyl.

25. A compound according to Claim 24 selected from the group consisting of:






or a pharmaceutically acceptable salt of any of the above.

26. A compound according to Claim 1 of Formula Ig:


5



Ig


10 or a pharmaceutically acceptable salt thereof, wherein:

A is selected from -N- or -CH-;



the group is selected from the group consisting of:

15



R¹ and R² are -H, or R¹ and R² may be joined together with the atoms to which they are attached to form cyclopropyl;

5

U and V are -C(R⁹)-;

each R⁹ is -H, or

- 10 For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R⁹ is attached;


- 15 R^a is selected from the group consisting of: thienyl, NR⁷R⁸, C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy and C₃₋₆cycloalkoxy, wherein said C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy and C₃₋₆cycloalkoxy are each optionally substituted from one up to the maximum number of substitutable positions with fluoro;


- 20 R⁷ and R⁸ are independently selected from the group consisting of: -H and C₁₋₆alkyl, optionally substituted with one to three fluoro groups, and


R⁷ and R⁸ may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, said ring is optionally substituted with one to three fluoro groups.


5

27. A compound according to Claim 26 selected from the group consisting of:










or a pharmaceutically acceptable salt of any of the above.

28. A compound according to Claim 1 of Formula Ih:

5











Ih

or a pharmaceutically acceptable salt thereof, wherein:

10

A is selected from $-N-$ or $-CH-$;



;

- 5 R¹ and R² are -H, or R¹ and R² may be joined together with the atoms to which they are attached to form cyclopropyl;

R⁵ is -H or -CH₃;

- 10 U and V are -C(R⁹)-;

each R⁹ is -H, or

- 15 For U or V, R⁹ and R¹ or R⁹ and R² may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R⁹ is attached;

R^a is selected from the group consisting of: -F, NR⁷R⁸, C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy and C₃₋₆cycloalkoxy, wherein said C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy and C₃₋₆cycloalkoxy


are each optionally substituted from one up to the maximum number of substitutable positions with fluoro;


R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6} alkyl, optionally substituted with one to three fluoro groups, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, said ring is optionally substituted with one to three fluoro groups;

R^b is Cl or I;

J is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, $-CONHSO_2R^{13}$, $-PO(R^{13})OH$,





R¹³ is selected from the group consisting of: C₁-C₄ alkyl, phenyl, -CH₂OH and CH(OH)-phenyl; and

5

each R¹⁴ is independently selected from the group consisting of: -H and -CH₃.

29. A compound according to Claim 28, wherein:


10 For U, R⁹ and R¹ are joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R⁹ is attached;

R⁵ is CH₃;

15

R^b is Cl; and


J is selected from the group consisting of: -CO₂H,





, wherein each R¹⁴ is independently selected


20 from the group consisting of: -H and -CH₃.


30. A compound according to Claim 28 selected from the group consisting of:











or a pharmaceutically acceptable salt of any of the above.